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Rift Valley fever (RVF) is a severe mosquito-borne 
disease affecting humans and domestic ruminants, 
caused by a Phlebovirus (Bunyaviridae). It is wide-
spread in Africa and has recently spread to Yemen 
and Saudi Arabia. RVF epidemics are more and more 
frequent in Africa and the Middle East, probably in 
relation with climatic changes (episodes of heavy rain-
fall in eastern and southern Africa), as well as inten-
sified livestock trade. The probability of introduction 
and large-scale spread of RVF in Europe is very low, 
but localised RVF outbreaks may occur in humid areas 
with a large population of ruminants. Should this hap-
pen, human cases would probably occur in exposed 
individuals: farmers, veterinarians, slaughterhouse 
employees etc. Surveillance and diagnostic methods 
are available, but control tools are limited: vector con-
trol is difficult to implement, and vaccines are only 
available for ruminants, with either a limited efficacy 
(inactivated vaccines) or a residual pathogenic effect. 
The best strategy to protect Europe and the rest of the 
world against RVF is to develop more efficient surveil-
lance and control tools and to implement coordinated 
regional monitoring and control programmes.
Relevance of Rift Valley fever to public 
health in the European Union 
Rift Valley fever (RVF) is a zoonotic disease of domestic 
ruminants and humans caused by an arbovirus belong-
ing to the Phlebovirus genus (family Bunyaviridae). It 
causes high mortality rates in newborn ruminants, 
especially sheep and goats, and abortion in pregnant 
animals. Human infection by the RVF virus (RVFV) may 
result from mosquito bites, exposure to body fluids of 
livestock or to carcasses and organs during necropsy, 
slaughtering, and butchering [1].
The public health impact of RVF can be severe. In Egypt 
in 1976, 200,000 people were infected and 600 fatal 
cases officially reported, among others in the River 
Nile delta [2]. Over 200 human deaths were reported in 
Mauritania in 1987 [3]. In 2007-2008, 738 human cases 
were officially reported in Sudan, including 230 deaths 
[4]. It is likely that the number of cases was underre-
ported because RVF mostly affects rural populations 
living far from public health facilities. The occurrence 
of RVF in northern Egypt is evidence that RVF may occur 
in Mediterranean countries, thus directly threatening 
Europe.  In the Indian Ocean, RVF has been introduced 
in the French island of Mayotte, with several clinical 
cases reported in humans [5]
Transmission, epidemiology 
and clinical symptoms
The RVFV transmission cycle involves ruminants and 
mosquitoes. Host sensitivity depends on age and ani-
mal species [6] (Table 1). Humans are dead-end hosts. 
The epidemiological cycle is made more complex by 
direct transmission from infected ruminants to healthy 
ruminants or humans, by transovarian transmission 
in some mosquito species, and by a large number of 
potential vectors with different bio-ecology [6]. The 
existence of wild reservoir hosts has not been clearly 
demonstrated to date (Figure 1).
Transmission mechanisms 
The bite of infected mosquitoes is the main transmission 
mechanism of RVF in ruminants during inter-epizootic 
periods. More than 30 mosquito species were found to 
be infected by RVFV [6,7] (Table 2), belonging to seven 
genera of which Aedes and Culex are considered as the 
most important from the point of view of vector com-
petence (other genera are Anopheles, Coquillettidia, 
Eretmapodite, Mansonia and Ochlerotatus). 
In mosquitoes, transovarian RVFV transmission has 
been observed in Aedes mcintoshi. It appears to be a 
likely phenomenon in several other species, including 
the widespread Ae. vexans species complex. In some 
of these Aedes species, infected, diapaused eggs may 
survive in dried mud during inter-epizootic and/or dry/
cold periods [8] and hatch infected imagos.
Ruminant-to-human transmission is the main infection 
route for humans, although they can also be infected 
2 www.eurosurveillance.org
by mosquito bites [9]. Body fluids such as the blood 
(during slaughtering and butchering), foetal mem-
branes and amniotic fluid of viraemic ruminants are 
highly infective for humans. Fresh and raw meat may 
be a source of infection for humans, but the virus is 
destroyed rapidly during meat maturation. Empirical 
field observations indicate that ruminants can also 
become infected by contact with material containing 
virus (e.g. fetus and fetal membranes after abortion), 
however, this route of transmission has not yet been 
confirmed [10].
Table 1
Species susceptibility and sensibility to the Rift Valley fever virus
Mortality >70% Mortality 10-70% Severe disease with low fatality rate (<10%) Antibody production Not susceptible
Lamb Sheep Human Camel Bird
Kid Calf Cattle Horse Reptile
Puppy Some rodents Goat Cat Amphibian
Kitten African Buffalo Dog
Mouse Asian Buffalo Swine
Rat Monkey Donkey
Rabbit
Reproduced from Lefèvre et al. [5] with permission from the publisher (Lavoisier, France)
Figure 1
Epidemiological cycle of Rift Valley fever
Human
Ruminant
Ruminant
Vectorial transmission
Direct transmission
Vertical transmission
Some Culex and other mosquito species
Wild vertebrate hosts ???
Infected mosquito eggs
Some Aedes mosquito species
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Table 2
Arthropods naturally infected by Rift Valley fever virus
Genus Species Country (year)
Aedes (Aedimorphus) cumminsii Kenya (1981-1984)
Burkina Faso (1983)
dalzieli Senegal (1974, 1983)
dentatus Zimbabwe (1969)
durbanensis Kenya (1937)
ochraceus Senegal (1993)
tarsalis Uganda (1944)
vexans arabiensis
Senegal (1993)
Saudi Arabia (2000)
Aedes (Neomelaniconion) circumluteolus
Uganda (1955)
South Africa (1955, 1981)
mcintoshi
Zimbabwe (1969)
South Africa (1974-1975)
Kenya (1981-1984)
palpalis Central African Republic (1969)
Ochlerotatus (Ochlerotatus) caballus South Africa (1953)
caspius Suspected, Egypt (1993)
juppi South Africa (1974-1975)
Aedes (Stegomya) africanus Uganda (1956)
demeilloni Uganda (1944)
Aedes (Diceromya) furcifer group Burkina Faso (1983)
Anopheles (Anopheles) coustani
Zimbabwe (1969)
Madagascar (1979)
fuscicolor Madagascar (1979)
Anopheles (Cellia) chrityi Kenya (1981-1984)
cinereus South Africa (1974-1975)
pauliani Madagascar (1979)
pharoensis Kenya (1981-1984)
Culex (Culex) spp. Madagascar (1979)
antennatus
Nigeria(1967-1970)
Kenya (1981-1984)
neavi South Africa (1981)
pipiens Egypt (1977)
poicilipes Senegal (1998, 2003)
theileri
South Africa (1970)
Zimbabwe (1969)
tritaeniorhynchus Saudi Arabia (2000)
vansomereni Kenya (1981-1984)
zombaensis
South Africa  (1981)
Kenya (1981-1984, 1989)
Culex (Eumelanomya) rubinotus Kenya (1981-1984)
Eretmapodites chrysogaster Uganda (1944)
quinquevittatus
South Africa (1971)
Kenya (1981-1984)
Coquillettidia fuscopennata Uganda (1959)
grandidieri Madagascar (1979)
Mansonia (Mansoniodes) africana
Uganda (1959, 1968)
Central African Republic (1969)
Kenya (1989)
uniformis
Uganda (1959)
Madagascar (1979)
Other diptera Culicoides spp. Nigeria (1967)
Adapted from [1].
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Direct human-to-human transmission has not been 
reported, and RVF is not considered to be a nosocomial 
disease. Transplacental RVFV transmission may occur 
in vertebrates, including humans. It results in abortion 
and high newborn mortality rates [11]. 
Rodents may be infected during epizootic periods [12-
15] but their epidemiological role in virus transmission 
and maintenance is not clear. Bat species also have 
been suspected [16]. Finally, wild ruminants may play 
a role in the epidemiology of RVF in areas where their 
population density is high [17]. 
Clinical features 
Animals
Clinical manifestations vary depending on age and 
animal species. In sheep, a fever of up to 41-42°C is 
observed after a short incubation period. Newborn 
lambs (and sometimes kids) usually die within 36 to 
40 hours after the onset of symptoms, with mortality 
rates sometimes reaching 95%. Older animals (from 
two weeks to three months-old) either die or develop 
only a mild infection. In pregnant ewes, abortions are 
frequent, ranging from 5% to 100%. Twenty per cent of 
the aborting ewes die. Vomiting may be the only clini-
cal sign presented by adult sheep and lambs older than 
three months. However, these animals may experience 
fever with depression, haemorrhagic diarrhoea, blood-
stained muco-purulent nasal discharge, and icterus. 
Case-fatality rates vary between 20% and 30%. Adult 
goats develop a mild form of the disease, but abor-
tions are frequent (80%). Mortality rates are generally 
low [10]. Calves often develop acute illness, with fever, 
fetid diarrhoea, and dyspnoea. Mortality rates may 
vary from 10% to 70%. Abortion is often the only clini-
cal sign and mortality rates are low (10-15%). 
Humans
In most cases, human infections remain unapparent, or 
with mild, influenza-like symptoms. However, infected 
people may experience an undifferentiated, severe, 
influenza-like syndrome and hepatitis with vomit-
ing and diarrhoea. Complications may occur. Severe 
forms are manifested in three different clinical syn-
dromes. The most frequent one is a maculo-retinitis, 
with blurred vision and a loss of visual acuity due to 
retinal haemorrhage and macular oedema. Encephalitis 
may also occur, accompanied by confusion and coma. 
This form is rarely fatal but permanent sequelae are 
encountered. The third and most severe form is a 
haemorrhagic fever, with hepatitis, thrombocytopenia, 
icterus, and multiple haemorrhages. This form is often 
fatal [10,18,19]. Human case-fatality rates have been 
lower than 1% in the past, however, an increase has 
been reported since 1970 [19]. In the RVF epidemic in 
Saudi Arabia in the year 2000, the fatality rate reached 
14% [20].
Diagnostic methods
RVFV presents a high biohazard for livestock farmers, 
veterinarians, butchers, slaughterhouse employees, 
and laboratory staff handling infected biological sam-
ples. International public health agencies have set a 
bio-safety level (BSL) of BSL3 for facilities in Europe 
handling the virus and of BSL4 for facilities in the 
United States (US).
Appropriate diagnostic samples are peripheral blood 
collected on EDTA, plasma or serum of infected animals 
or patients, and the liver, brain, spleen or lymph nodes 
of dead animals. When samples can be conveyed rap-
idly to a diagnostic laboratory (<48 hours), they should 
be stored at a temperature below +4 °C. When this is 
not the case, samples should be frozen at -20 °C (or 
below). Small fragments of organs may be stored in a 
10-20% glycerol solution 
Virus isolation can be performed in suckling or weaned 
mice by intracerebral or intraperitoneal inoculation 
or in a variety of cell cultures including Vero, BHK21, 
or mosquito line cells. RVFV can be identified in cell 
cultures by immunofluorescence, virus neutralisation 
test, reverse transcriptase polymerase chain reaction 
(RT-PCR), and/or genome sequencing. Virus isolation 
is the gold standard for RVF diagnosis. However, its 
sensitivity is rather low: RVFV isolation is not easy to 
achieve. Alternatively, the detection of RVFV ribonu-
cleic acid (RNA) can be done using RT-PCR performed 
on RNA extracted directly from biological samples 
[21]. Results are available within a few hours, which 
makes RT-PCR the priority test when a case of RVF is 
suspected.
Serological tests to detect antibodies against RVFV 
include the virus neutralisation test (VNT), and enzyme-
linked immunosorbent assays (ELISA). VNT is very spe-
cific, cross reactions with other Phleboviruses being 
limited [22;23]. It is the gold standard serological test. 
However, it is costly, time consuming, and requires a 
BSL3 or 4 laboratory.
(Indirect) immunoglobulin (Ig) detection ELISAs are 
quick, sensitive and specific. They are progressively 
replacing VNT [24]. A competition ELISA (cELISA) is also 
commercially available to detect IgG and IgM. It allows 
serological diagnosis in ruminants and humans. At the 
earliest, it can detect antibodies as soon as four days 
following infection or vaccination in animals reacting 
very early, and eight days post-vaccination for 100% 
of animals [25]. More recently, another indirect ELISA 
based on a recombinant RVFV nucleoprotein has been 
developed. Its sensitivity is 98.7% and specificity 
99.4% [26-28].
The cELISA has been evaluated with human and animal 
sera collected in Africa, and also with sera from French 
livestock (cattle, sheep and goats) to check their spe-
cificity with European ruminant breeds which turned 
out to be excellent with a predictive negative value of 
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100% (n = 502), 95% confidence interval: 99.3 to 100% 
[29].
Treatments
There is no specific treatment for either humans or 
animals. 
Prevention 
Vaccines
A human vaccine (inactivated with beta-propiolactone) 
has been produced in the US and was used to protect 
laboratory staff and military troops. However, its pro-
duction has been stopped [30].
Given that domestic ruminants are involved in the epi-
demiological cycle and that humans mostly become 
infected after contact with viraemic animals, the vacci-
nation of ruminants is the method of choice to prevent 
human disease. Both live and inactivated vaccines are 
available for livestock. 
The Smithburn vaccine is a live attenuated vaccine. It 
is inexpensive to prepare and immunogenic for sheep, 
goats, and cattle. It protects these species against 
abortion caused by a wild RVFV, and post-vaccinal 
immunity is life long. However, it has a residual patho-
genic effect and may induce foetal abnormalities and/or 
abortion in ruminants. It is also pathogenic for humans 
(febrile syndrome). Despite these drawbacks, it is rec-
ommended by the Food and Agriculture Organization 
of the United Nations (FAO) [31] and remains the most 
widely used vaccine against RVF in Africa. 
The inactivated RVF vaccine provides a lower level 
of protection and its production is more expensive. 
Moreover, it requires at least two inoculations and 
frequent booster shots to induce the desired level of 
protection, rendering it inappropriate in countries 
where large portions of ruminant herds are nomadic. 
However, it was used by the Israeli veterinary services 
to prevent RVF introduction to Israel after the 1977-
1978 epidemic in Egypt [32], as well as by the Egyptian 
veterinary services to prevent re-introduction of RVF 
from Sudan after an epidemic hit that country in 2007.
Other candidate vaccines are being evaluated such as 
the so-called “clone 13” which is an attenuated strain of 
RVFV that was isolated from a moderately ill patient in 
the Central African Republic [33]. This vaccine induces 
neutralising antibodies against RVFV. New-generation 
vaccines are also under study: recombinant vaccines 
using a poxvirus or an Alphavirus-based vector [34,35] 
and DNA vaccines [34*,36*]. However, these vaccines 
are still in the preliminary stages of development.
Smithburn and inactivated vaccines are produced and 
commercially available in Egypt, South Africa, and 
Kenya. There is no Community pharmaceutical leg-
islation prohibiting companies from producing RVF 
vaccines on EU territory and there is no obligation to 
notify such production to the European Commission. 
Moreover, quoting Council Directive 2001/82/EC (EC 
2OO1b), “in the event of serious epizootic diseases, 
Member States may provisionally allow the use of 
immunological veterinary medicinal products without a 
marketing authorisation, in the absence of a suitable 
medicinal product and after informing the Commission 
of the detailed conditions of use (article 8)” [37*].
Insecticide treatments
Larvicide treatments may provide a control alternative 
where mosquito breeding sites are well identified and 
cover limited surface areas. Both Methoprene, a hor-
monal larval growth inhibitor, and Bacillus thuringien-
sis israeliensis (BTI) preparations, a microbial larvicide, 
are commercially available and can be used success-
fully to treat temporary ponds and watering places 
where mosquitoes proliferate. Adulticide treatments 
(e.g. using pyrethroids) are expensive and difficult to 
implement. Moreover, because this usually involves 
treating large areas, the environmental and ecological 
consequences may be important.
Other measures
Preventive measures should also include restrictions 
on animal movements, the avoidance or control of 
the slaughter and butchering of ruminants, the use of 
insect repellents and bed nets during outbreaks, infor-
mation campaigns, and increased and targeted surveil-
lance of animals, humans and vectors.
Current geographical distribution
RVF is either enzootic, or is reported in most sub-Saha-
ran African countries, Egypt and Madagascar (Figure 
2). 
During the first large epidemic, reported in Egypt in 
1977-1978, over 600 people died of RVF [39]. The epi-
demic reached the Mediterranean shore (Nile delta) but 
did not spread to neighbouring countries. In September 
2000, RVF was detected for the first time outside of 
the African continent in Saudi Arabia and Yemen, and 
led to human deaths and major livestock losses [40]. 
By the end of 2006, the disease had re-emerged in 
Kenya [41], followed by Tanzania and Somalia [42]. 
Another large epidemic hit the Sudan in 2007 in the 
Nile Valley around Khartoum [4]. In May 2007, RVF 
was diagnosed on the French island of Mayotte in a 
young boy who had been evacuated from Anjouan, one 
of the other islands of the Comoros archipelago. The 
RVFV was probably introduced there by the trade of 
live ruminants imported from Kenya or Tanzania during 
the 2006-2007 epidemics. Studies conducted after this 
first human case was reported have shown that 10% of 
cattle had antibodies against RVFV (ELISA, IgG and/or 
IgM) - without any clinical suspicions reported by the 
public and private veterinary services. A retrospective 
study was then conducted in 2008, using blood sam-
ples collected from clinically suspected human cases 
of dengue or chikungunya illness who had tested neg-
ative for these two diseases, between 1 September 
2007 and 31 May 2008. Ten human RVF cases were 
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found (including IgM- and/or RT-PCR-positive sam-
ples), seven of them (70%) occurring from January to 
April, during the hot, rainy season [5]. This study has 
demonstrated that RVF had been circulating in Mayotte 
at least since early 2007, probably introduced there by 
the illegal importation of live infected ruminants from 
other Comoros islands.
In 2008, a RVF epidemic occurred in Madagascar with 
over 500 human cases [43]. Several outbreaks were 
reported in South Africa in late 2007 and 2008 without 
any reported human cases [44]. 
Factors of change
Factors that could cause a change in the epidemiol-
ogy of RVF are summarised in Table 3. Irrigated areas, 
including rice fields, constitute favourable breeding 
sites for many mosquito species. Dambos are tempo-
rary surface water bodies found in semi-arid eastern 
Africa. With heavy rainfall and consecutive flooding, 
considerable mosquito proliferation may occur (mostly 
Aedes and Culex spp.). Wadi are temporary rivers 
encountered in arid areas (e.g. Yemen or Saudi Arabia): 
when they stop flowing, surface water remains avail-
able in ponds and mosquitoes may proliferate.
Livestock trade and the Mediterranean region
Livestock trade and transport may affect the geograph-
ical distribution of RVF and contribute to a large scale 
– sometimes continental - spread of the disease and to 
the introduction of the virus into disease-free areas via 
livestock movements. RVF cases were reported in irri-
gated areas of the Sudan during the 1970s. Antibodies 
were detected in camels that crossed the border from 
Sudan to Egypt, suggesting that infected camels may 
have introduced RVFV into Egypt [39]. 
Figure 2
Geographical distribution of Rift Valley fever
Source: United States Centers of Disease Control and Prevention 
[38*].
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Table 3
Main outbreaks of Rift Valley fever and factors causing them
Year Country Ecosystem Vector Hosts Triggering factor
1975 South Africa ? ? ? ?
1976 Sudan Irrigated area ? Small ruminants Irrigation (?)
1977 Egypt Irrigated area Culex pipiens Small ruminants, camels, humans Irrigation, cattle trade
1987 Mauritania, Senegal Irrigated area Culex pipiens Small ruminants, cattle, camels, humans ?
1993 Egypt Irrigated area ? Small ruminants, humans Irrigation
1997 Egypt Irrigated area ? Small ruminants, humans Irrigation
1997-1998 Kenya Dambos
Aedes spp.
Culex zombaensis
Small ruminants Rainfall
2000 Yemen, Saudi Arabia Wadi
Aedes vexans
Culex tritaeniorhynchus
Small ruminants, cattle, 
camels, humans Rainfall and virus introduction
2006-2007 Kenya, Tanzania, Somalia Dambos ?
Small ruminants, cattle, 
humans Rainfall
2007 Sudan Irrigated area ? Small ruminants, cattle, humans ?
2007-2008 Mayotte Island ? Small ruminants, cattle, humans Virus introduction
2008 Madagascar Rice field in highlands
Culex?
Anopheles?
Small ruminants, cattle, 
humans ?
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During the outbreak in Saudi Arabia in 2000, six viral 
strains of RVFV were isolated from Aedes mosquitoes. 
These strains were genetically close to the strain iso-
lated in Kenya (1997-1998), suggesting that the virus 
was probably introduced into Saudi Arabia from the 
Horn of Africa by ruminants [45]. It remains unknown 
whether the virus has survived in Saudi Arabia since 
2000. In any event, the risk of re-introduction from the 
Horn of Africa is high. During the period of religious 
festivals in Mecca, 10 to 15 million small ruminants are 
imported from there to Saudi Arabia.
A similar pattern in sheep trade is observed between 
sub-Saharan Africa and northern Africa. In the coming 
years, the Muslim feasts of Eid-ul-Fitr and Eid al-Adha 
will occur between September and November, i.e. when 
the activity of mosquito populations is high (end of the 
rainy season in Sahelian Africa) [46].
Therefore, the introduction of RVF-infected animals on 
the eastern and southern shores of the Mediterranean 
Sea is a likely event. Once introduced there, RVFV may 
find ruminant hosts, as well as competent mosquito 
species [47]. However, because livestock trade from 
northern Africa and the Middle East to Europe is forbid-
den, the introduction of RVF-infected animals to Europe 
looks unlikely [48].
Climate
Climate warming is likely to have an impact on the 
geographical distribution of RVF. Higher temperatures 
increase mosquito feeding frequency and egg produc-
tion and decrease the duration of their development 
cycle, as well as the extrinsic incubation period of RVFV 
in mosquitoes. Therefore, higher temperatures associ-
ated with increased rainfall may result in higher vector 
densities and vector competence and, subsequently, a 
higher RVFV transmission rate. In addition, transovar-
ian transmission processes could be altered.
If the virus were introduced to northern Africa or south-
ern Europe, mosquitoes such as Ae. vexans could play 
a role as vectors in many Mediterranean countries. 
Several Ochlerotatus species, which breed in wetlands, 
might also be able to transmit the virus. Culex pipiens, 
a ubiquitous species, is locally abundant (in wetlands, 
rice fields, irrigated crops, sewers etc) and may act 
as an amplifier in the biological cycle. Increased tem-
peratures could also have an impact on the vector 
competence and capacity of other endemic European 
mosquito species [49], although this is difficult to 
quantify (it has already been proved in controlled con-
ditions with other arboviruses). Indeed, if introduced, 
several potential vector species that have so far not 
been investigated may become involved in the trans-
mission of the RVFV.
In East Africa, RVFV causes major epidemics at irreg-
ular intervals of 5-15 years. Climate models for this 
region predict an increase in the mean annual rainfall 
as well as an increase in the frequency and intensity 
of extreme rainfall events [50]. These changes may 
induce more severe and more frequent outbreaks in 
East Africa, which would thus represent a high risk 
area for neighbouring regions with livestock trade rela-
tionships such as the Indian Ocean islands.
Vectors
The flight capacities of Aedes and Culex mosquitoes 
are somewhat limited, ranging from a few hundred 
meters to more than 10 km [51,52]. However, these dis-
tances are long enough to allow a local spread of RVF. 
Wind transportation of infected mosquitoes has been 
reported for other arboviruses [53,54]. Presently, no 
information is available for RVFV vectors. Passive 
transportation of infected mosquitoes in boats or 
planes travelling from Africa has been reported for 
Anopheles mosquitoes infected by Plasmodium para-
sites [55]. However, for RVFV to be introduced this way, 
such infected mosquitoes would need to find suscep-
tible hosts to initiate a local cycle. This event looks 
unlikely.
Predictive models 
Risk mapping 
East Africa (Kenya)
In Kenya, a correlation has been demonstrated between 
heavy rainfall events and the occurrence of RVF out-
breaks. Maps of remotely sensed rainfall as well as 
vegetation index maps have been used together with 
ground data to monitor and predict vector population 
dynamics and RVFV activity and have established a 
correlation between these two parameters. The main 
advantage of remote sensing for the prediction of RVF 
occurrence in East Africa is the relatively low cost. It 
is readily available on a country and regional basis 
and its use may allow preventive measures to be taken 
such as the vaccination of susceptible livestock and 
the control of mosquito larvae [56,57].
Predictive models have been improved over the past 
decade through the addition of Pacific and Indian 
Ocean surface temperature anomalies and rainfall and 
normalised difference vegetation index (NDVI) data. An 
accuracy of 95-100% was estimated for the prediction of 
Kenyan epizootics of RVF, with a lead time of two to five 
months [57]. The FAO has used the technology to warn 
countries facing an increased risk of RVF. However, the 
geographic scope of these models is limited because 
ecological and epidemiological processes are different 
in other areas of Africa [58]. The outlook for the use 
of these models is even worse for the Mediterranean 
basin and Europe where climate determinants differ 
significantly from those of East Africa and the potential 
ecological and epidemiological processes are unknown 
as the disease has never been reported in these areas.
West Africa (Senegal)
RVF is endemic in the Ferlo area (northern Senegal) 
[59]. This area is characterised by a temporary pond 
ecosystem. These ponds are filled at the beginning 
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of the rainy season (July) and dry up from October to 
January, according to their size and the intensity of 
rainfall, and are favourable environment to the devel-
opment of Aedes mosquito populations.
However, the East African model can not be applied 
in West Africa: abundant rainfall is not often associ-
ated with RVF outbreaks. The epidemiological process 
leading to RVF epidemics looks much more complex, 
Table 4
Competent mosquito vectors of Rift Valley fever virus with known distribution in the European Union and candidate 
countries
Country Aedes vexans vexans Ochlerotatus caspius Culex theileri Culex pipiens Culex perexiguus
Austria X X ? X ?
Belgium X X ? X ?
Bulgaria X X X X X
Croatia1 X X ? X ?
Cyprus ? X ? X ?
Czech Republic X X ? X ?
Denmark X X ? X ?
Estonia X X ? X ?
Finland X X ? X ?
France (mainland) X X X X ?
France (Corsica) X X X X ?
Germany X X ? X ?
Greece X X X X X
Hungary X X X X ?
Ireland ? X ? X ?
Italy (mainland) X X X X X
Italy (Sardinia) X X X X ?
Italy (Sicily) X X X X X
Latvia X X ? X ?
Lithuania X X ? X ?
Luxembourg ? ? ? ? ?
Former Yugoslav Republic of Macedonia1 X X X X X
Malta ? X ? X ?
The Netherlands X ? ? X ?
Poland X X ? X ?
Portugal X X X X X
Romania X X X X ?
Slovakia X X X X ?
Slovenia X X ? X ?
Spain (mainland) X X X X X
Spain (Balearic Islands) X ? ? X ?
Sweden X X ? X ?
Turkey1 X X X X X
United Kingdom X X ? X ?
X: vector present; ?: unknown to the authors, or not found yet.
1EU candidate country.
Adapted from [1]. 
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involving the joint dynamics of hosts movements (tran-
shumance), host immunity, and a vector population 
with brief activity during the rainy season.
In this region, the risk of transmission was shown to 
be heterogeneous and linked to pond type [59]. A very 
high spatial resolution remote sensing image was used 
to characterise the temporary ponds and their environ-
ment and derive indices linked to mosquito biology 
[60]. However, this work is not advanced enough to be 
used in surveillance programmes.
Risk analysis for Europe
A detailed, qualitative risk analysis was performed in 
2005 by The European Food Safety Authority (EFSA) 
[1]. The main conclusions of this study are summarised 
below. 
Ruminant importations
The importation of infected ruminants is the greatest 
hazard for RVF introduction to the European Union (EU). 
Clinical signs may not be observed rapidly in livestock 
living in remote, humid areas such as the Camargue 
region in France or the Danube delta in Romania. Such 
a scenario would allow RVFV to amplify and endemic 
foci to develop, if suitable ecological and entomologi-
cal conditions were met [1]. 
Official RVF-free status is required for a country to 
export livestock and livestock meat to the EU. Such 
a status depends on a country’s ability – relying on 
observable evidences - to implement an efficient dis-
ease surveillance system and willingness to report pos-
sible RVF outbreaks. These constraints are the same as 
for foot-and-mouth disease and other epizootic dis-
eases. They were instituted in 1972 (directive 72/462/
CEE [61], later modified to be more stringent). The prac-
tical consequence is that any introduction of live rumi-
nants and their products from Africa and the Middle 
East to the European Union is forbidden. However, 
illegal and unknown ruminant importations probably 
occur between the Middle East and central Europe, and 
between northern Africa and southern Europe. This is 
also a major component of the risk of introduction of 
many other important animal and zoonotic diseases, 
like peste des petits ruminants, foot–and-mouth dis-
ease, bluetongue disease, Crimean-Congo haemor-
rhagic fever, etc. For instance, a risk analysis has 
recently been conducted to assess the risk of introduc-
tion of peste des petits ruminants virus (a Morbillivirus) 
from Maghreb to France. The conclusion was that the 
risk was extremely low, ranging from 0 to 2 on a scale 
from 0 (impossible event) to 9 (certain event) [48]. 
Vectors
Several potential RVFV vectors are present in the EU 
(Tables 4 and 5). Differences in climate, seasonal varia-
tions of vector and host density, and genetic drift may 
result in differences in vector competence (the bio-
logical suitability of the vector to transmit the patho-
gen) and vectorial capacity (external factors such as 
number and lifespan of the vector, feeding preferences 
of the host) compared with the situation in Africa. 
Nevertheless, there is almost no doubt that several 
of the mosquito species in the EU, e.g. Cx. pipiens, 
would be competent vectors for RVF [62]. Moreover, 
the introduction and spread of new vector species 
represents a further risk. For example, Ae. albopictus 
can transmit RVFV [62-64], and many epidemiological 
concerns arise from this species’ current distribution 
in Europe: Albania, Bosnia and Herzegovina, Croatia, 
Italy (including Sicilia and Sardinia), south eastern con-
tinental France and Corsica, limited areas of Germany 
(north of the Alps), Greece, Monaco, Montenegro, the 
Netherlands (green houses), San Marino, Slovenia, 
eastern Spain, southern Switzerland, and the Vatican 
city [65].
Virus survival 
Blood, organs, fresh meat, fetal fluids and tissues as 
well as hides all represent a serious hazard to at-risk 
occupational groups (farmers, veterinarians, slaugh-
terhouse employees, butchers, etc). The virus persists 
in the liver, spleen and kidneys, but rapidly disappears 
from meat as the pH decreases with meat maturation. 
The importance of blood, bone and offal meal products 
as a vehicle for RVFV has not been evaluated [4]. Milk 
is not considered to constitute a risk. However, due to a 
lack of data, transmission by ingestion of milk can not 
be definitively ruled out. 
Accidental RVF infections have been recorded in labo-
ratory staff handling blood and tissues from infected 
animals. 
Conclusion
Several national and Commission-supported analyses 
have been conducted to assess the risk of the intro-
duction and spread of RVF within the EU. The conclu-
sions have been that the overall risk was low. However, 
the recent reappearance of RVF in East Africa, includ-
ing Sudan, the Nile Valley, and the Indian Ocean, has 
shown that the RVFV is very active and sensitive to 
climate and other environmental as well as socio-eco-
nomic changes. These changes, together with grow-
ing human populations and an associated increased 
demand for meat, will promote greater controlled and 
uncontrolled movements of livestock. Consequently, 
the Mediterranean basin, central Europe, and the 
Middle East will probably be increasingly exposed to 
the risk of introduction of RVF. It is important to pro-
mote risk analyses that rely on accurate estimations 
of livestock movements between endemic and RVF-
free areas. Moreover, high-risk ecosystems should be 
catalogued and the data updated on a regular basis to 
account for environmental changes. This latter activ-
ity has been initiated under the EU-funded Emerging 
Diseases in a changing European eNvironment (EDEN) 
project and should be continued once the project ends 
in 2010. Research programmes are needed to better 
characterise the bionomics of RVFV vectors in Europe 
and to develop RVFV introduction, installation, and 
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spread models to improve disease surveillance and 
provide more efficient decision-making tools.
Furthermore, more efficient vector and disease control 
methods are needed to enable the implementation of 
efficient contingency plans:
- For vector control, a systematic assessment of exist-
ing methods and tools should be undertaken (labora-
tory and field experiments) and research programmes 
developing new technologies should be supported, 
including options for the development of genetically 
modified mosquitoes designed either to reduce popu-
lation sizes or to replace existing populations with vec-
tors unable to transmit the disease.
- For disease control in European ruminants, the exist-
ing vaccines should be tested, preferably in collabo-
ration with pharmaceutical companies. Because the 
cheapest and most efficacious existing vaccine (the 
Smithburn RVFV strain) has residual pathogenic effects 
in ruminants and humans, research on new-generation 
vaccines (e.g. recombinant, or reverse-genetic vac-
cines) should also be supported, both for human and 
animal populations.
- Because a large-scale RVF epidemic appears unlikely 
in Europe (where a low proportion of people have direct 
contact with ruminants and their body fluids), human 
vaccination should target the population subgroups at 
high risk of exposure (farmers, veterinarians, slaugh-
terhouse employees, butchers etc), once human vac-
cines have been developed.
- Finally, the most relevant long term strategy is to 
control RVF where it is endemic. A substantial effort is 
needed to better understand the bio-ecology of RVFV 
vectors and viruses and epidemiological processes in 
Africa, to develop predictive and quantitative risk mod-
els and maps, and to implement risk-based surveil-
lance and control methods.
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